Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lowered its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 71.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 163,300 shares of the company's stock after selling 408,927 shares during the quarter. Schonfeld Strategic Advisors LLC owned approximately 0.24% of Replimune Group worth $1,978,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of REPL. Price T Rowe Associates Inc. MD raised its stake in Replimune Group by 11.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after purchasing an additional 1,083,633 shares during the period. Marshall Wace LLP purchased a new position in Replimune Group during the fourth quarter worth approximately $10,853,000. Wellington Management Group LLP raised its stake in Replimune Group by 352.5% during the fourth quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock worth $13,282,000 after purchasing an additional 854,346 shares during the period. Artisan Partners Limited Partnership purchased a new position in Replimune Group during the fourth quarter worth approximately $7,399,000. Finally, Rosalind Advisors Inc. purchased a new position in Replimune Group during the fourth quarter worth approximately $3,149,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Wall Street Analyst Weigh In

REPL has been the topic of a number of recent analyst reports. HC Wainwright increased their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Finally, BMO Capital Markets increased their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $19.43.

Replimune Group Trading Down 0.8%

Shares of REPL stock traded down $0.06 during mid-day trading on Friday, reaching $7.71. The company's stock had a trading volume of 1,352,895 shares, compared to its average volume of 899,337. The company's 50 day simple moving average is $9.36 and its 200-day simple moving average is $11.48. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $593.79 million, a PE ratio of -2.51 and a beta of 0.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, research analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.